Country Focus
Market Analysis
First posted: 14 November 2012
Concerning the 2013 status of generics market in China, view the following related article:
- The enormous population growth and the outbreak of chronic disorders and communicable diseases have driven the Chinese Government to resort to cost-effective healthcare solutions [1].
- Market shares of generic medicines in terms of value have increased from 54% in 2000 to 63% in 2010 [1], while the volume of consumption of generic medicines was 95.1% in 2011 [2].
Market Analysis
First posted: 8 October 2013
The market share of generic medicines by value has only risen slightly in Germany since 1994. Public expenditure on generic medicines rose from 32.2% of the market share by value in 1994 to 36.8% of the market share by value in 2008 [1].
Market Analysis
First posted: 22 November 2013
Poland has a mature generic medicines market. Irrespective of whether the shares are expressed by value or by volume, market shares of generic medicines fell in the 1990s, but stabilised in the early 2000s [1].
Market Analysis
The Dutch generic medicines market has grown rapidly over time, with public expenditure increasing from Euros 185 million in 1994 (market share by value of 8.5%) to Euros 830 million in 2004 (market share by value of 17.7%) and to up to approximately Euros 977 million in 2007 (market share by value of 21%). Introduction of various policies by both the government and health insurance companies reduced public expenditure in 2008 to Euros 711 million (market share by value of 15%) [1].
Market Analysis
Belgium had a small generic medicines market during the second half of the 1990s. Its development was boosted by the introduction of a reference-pricing system in 2001. Public expenditure on generic medicines rose from Euros 18 million in 1994 (market share by value of 0.8%) to Euros 213 million in 2004 (market share of 4.8%) [1].
Others
The UK is already a mature (well-established) market* in the use of generic medicines.
Others
The Spanish pharmaceutical market is poorly developed* in the use of generic medicines.
Others
Denmark is already a mature (well-established) market* in the use of generic medicines.
Others
First posted: 16 March 2012
The Portuguese generics market is poorly developed* and is one of the smaller markets in Europe by both volume and value.
Others
First posted: 26 April 2012
The Austrian generics market is poorly developed* and is one of the smaller markets in Europe by both volume and value.
